Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-4357 injection and HRS-5041 tablets, marking a significant step in the development of innovative cancer treatments [1] Group 1: Product Development - HRS-4357 injection is a self-developed innovative drug for radioactive therapy, now approved for clinical trials in combination with HRS-5041 for treating prostate cancer patients with PSMA positivity [1] - HRS-4357 injection has accumulated research and development investment of approximately 67.55 million yuan [1] - HRS-5041 is a new, efficient, and selective ARPROTAC small molecule aimed at treating prostate cancer, showing significant degradation effects on wild-type and most mutant AR proteins [1] Group 2: Market Position - Currently, there are no similar products approved for market release domestically or internationally for both HRS-4357 and HRS-5041 [1] - HRS-5041 has the potential to overcome resistance compared to second-generation AR inhibitors, indicating a competitive edge in the market [1] - The accumulated research and development investment for HRS-5041 is approximately 92.66 million yuan [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS9531 and HRS-5817 injection solutions, which will be conducted in overweight or obese adult patients [1] Group 1: Company Developments - Jiangsu Heng Rui Medicine Co., Ltd.'s subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has been granted the clinical trial approval notice for HRS9531 and HRS-5817 injection solutions [1] - The approval is based on the review under the Drug Administration Law of the People's Republic of China, confirming that the injection solutions meet the requirements for drug registration [1] Group 2: Clinical Trial Details - The clinical trials will focus on the combination treatment of HRS9531 and HRS-5817 injection solutions in adult patients who are overweight or obese [1] - The approval for the clinical trials was granted on October 14, 2025, indicating a timeline for the commencement of these studies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-003 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（ ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 中國上海 2026年1月5日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-002 ...

Core Insights - The pharmaceutical industry in 2025 experienced significant changes, particularly in the generic drug sector, marked by intense competition and regulatory challenges, with the race for first generic drugs becoming a central focus [1] Group 1: Market Dynamics - The 11th round of national drug procurement introduced optimized rules aimed at stabilizing clinical use, ensuring quality, and preventing price wars, marking a pivotal moment for the industry [2] - Over 277 first generic drugs were approved from 2022 to 2024, with a steady increase in numbers, indicating a resilient market despite challenging conditions [2] - In 2025, 959 generic drug varieties passed or were deemed to have passed consistency evaluations, with 207 being first approvals, accounting for over 20% of the total [2] Group 2: Leading Companies - In 2025, Kelun Pharmaceutical maintained its position as the leader in first generic drugs with 6 approvals, reinforcing its dominant market status [5] - Qilu Pharmaceutical followed closely with 5 first generic approvals, showcasing its strong R&D capabilities and market competitiveness [7] - Yichang Renfu Pharmaceutical and Hangzhou Muyuan Biopharmaceutical emerged as notable competitors, each achieving 3 first generic approvals, marking a significant rise in their market presence [8][9] Group 3: Regulatory Environment - A regulatory storm in December 2025 led to the rejection of 102 applications for chemical generics within a short span, highlighting the increased scrutiny on the authenticity and compliance of drug development [12] - This regulatory shift signals the end of a development model that prioritized speed over quality, emphasizing the need for stability and compliance in the race for first generics [12]

Market Overview - In December 2025, the A-share market showed a "high-level fluctuation and structural switching" pattern, with the Shanghai Composite Index rising by 2.06% and the Shenzhen Component Index increasing by 4.17%[7] - The average return of the stock portfolio in December was 6.20%, outperforming the CSI 300 Index, which rose by 2.28%[7] Stock Recommendations - **Hengrui Medicine (600276)**: Closing price at 59.57 CNY, focusing on innovative drugs with a projected EPS of 1.31 CNY for 2025[10][12] - **Luoyang Molybdenum (603993)**: Closing price at 20.00 CNY, benefiting from copper and gold business expansion, with an EPS forecast of 0.88 CNY[15][18] - **Huaxin Cement (600801)**: Closing price at 24.54 CNY, with a focus on overseas expansion and an EPS estimate of 1.42 CNY[19][22] - **Sanmei Co., Ltd. (603379)**: Closing price at 60.72 CNY, specializing in refrigerants, with an EPS forecast of 3.50 CNY[23][27] - **CATL (300750)**: Closing price at 367.26 CNY, with a valuation recovery theme and an EPS estimate of 15.00 CNY[28][31] - **Sungrow Power Supply (300274)**: Closing price at 171.04 CNY, benefiting from favorable conditions in new energy storage, with an EPS forecast of 7.12 CNY[32][35] - **Sany Heavy Industry (600031)**: Closing price at 21.13 CNY, focusing on engineering machinery with an EPS estimate of 0.99 CNY[36][39] - **Inovance Technology (300124)**: Closing price at 75.33 CNY, focusing on industrial control with an EPS forecast of 2.07 CNY[40][42] - **North Huachuang (002371)**: Closing price at 459.08 CNY, specializing in semiconductor equipment with an EPS estimate of 9.95 CNY[43][45] Risks and Considerations - The report indicates a medium to high risk level for the stock portfolio, emphasizing the need for cautious investment decisions based on the accuracy and completeness of the information provided[6][3] - Potential risks include macroeconomic fluctuations, raw material price volatility, and regulatory changes affecting industry dynamics[11][18][19]

Suspension and Resumption - ChuanYin High-Tech: The stock is suspended as the offer period for the acquisition by China Seed Group has expired [1] Private Placement - Weigao Blood Purification: Plans to issue shares to acquire 100% equity of Weigao Purui at a transaction price of 8.511 billion yuan [2] - Haopeng Technology: Plans to raise no more than 800 million yuan through a private placement for energy storage battery construction projects and steel shell stacked lithium battery projects [2] Equity Transfer and Increase - Tengya Precision: The controlling shareholder intends to transfer 5.7% of shares at a price of 14.47 yuan per share [3] - JinFang Energy: Yang Jianxun and his concerted parties plan to transfer a total of 10.46% of shares [4] - Hengyi Petrochemical: The controlling shareholder and concerted parties adjusted the share buyback price range from no more than 10 yuan per share to no more than 15 yuan per share [4] Daily Operations and External Investments - Fulian Precision: A subsidiary plans to invest a total of 8.7 billion yuan to build a project with an annual production capacity of 500,000 tons of high-end lithium iron phosphate for energy storage [5] - Defu Technology: A wholly-owned subsidiary signed a cooperation intention agreement with a well-known domestic CCL enterprise to supply high-end electronic circuit copper foil products [5] - Tianchen Medical: Signed a strategic cooperation agreement with Inspur Digital Technology (Shanghai) to jointly invest in R&D resources for medical robots [5] - Xusheng Group: Recently received a notification from a North American electric vehicle manufacturer for supplying components, with a project lifecycle of about 8 years and a total sales amount of approximately 7.8 billion yuan [5] - Jinguang Equipment: Plans to invest about 581 million yuan in the construction of the third phase of the complete equipment industrialization project for filtration [7] - Guizhou Tire: Plans to invest 299 million USD in Morocco to build an intelligent manufacturing project for semi-steel radial tires [9] - Zhejiang Mining: Plans to acquire 100% equity of Alaigyr Company, which owns lead-silver mines in Kazakhstan [10] - Feiwo Technology: Recently completed the acquisition of 60% equity in liquid rocket engine component company Xinsai Aerospace [11] - Tianci Materials: Plans to suspend production for maintenance on the 150,000-ton liquid lithium hexafluorophosphate production line at the Longshan North base [12] Performance Changes - Chifeng Gold: Expects a net profit of 3 billion to 3.2 billion yuan in 2025, an increase of approximately 70% to 81% year-on-year [13] - Dingtai High-Tech: Expects a net profit of 410 million to 460 million yuan in 2025, a year-on-year growth of 81% to 103% [13] - China National Materials: Expects a net profit of 1.55 billion to 1.95 billion yuan in 2025, a year-on-year increase of 73.79% to 118.64% [13] - Ugreen Technology: Expects a net profit of 653 million to 733 million yuan in 2025, a year-on-year growth of 41.26% to 58.56% [13] - Huayou Cobalt: Expects a net profit of 5.85 billion to 6.45 billion yuan in 2025, a year-on-year increase of 40.80% to 55.24% [13]

Group 1 - Postal Savings Bank announced a cash dividend distribution of 14.772 billion yuan for the first half of 2025, with a dividend of 1.23 yuan per 10 shares [1] - Xinke Mobile plans to reduce its shareholding by up to 1%, amounting to a maximum of 34.1875 million shares, due to funding needs [1] - Defu Technology signed a cooperation letter with a leading domestic CCL company to supply high-end electronic circuit copper foil products, which is expected to positively impact the company's performance in 2026 [1] Group 2 - Sanxia New Materials intends to acquire 40% equity of Lingang New Materials for a transaction amount of 0 yuan, which constitutes a related party transaction [2] - Fulim Precision plans to invest a total of 87 billion yuan in projects for the production of high-end lithium iron phosphate for energy storage, with the main project estimated at 60 billion yuan [3] - Heng Rui Pharmaceutical received approval for clinical trials of HRS9531 injection in combination with HRS-5817 injection for treating obesity in adults [3] Group 3 - Quartz Co. was fined 2.7 million yuan for commercial secret infringement, with the company being the victim in this case [5] - ST Renfu received approval for clinical trials of HW221043 tablets for late-stage solid tumors, with no similar drugs approved domestically or internationally [6] - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical robotics and smart manufacturing [6] Group 4 - Xusheng Group received a notification from a North American electric vehicle manufacturer for a project with an estimated total sales amount of approximately 7.8 billion yuan over its lifecycle [6] - Deyun Co. announced that its actual controller was arrested for illegal public deposit collection, but this does not significantly impact the company's operations [7] - Shengyang Technology's subsidiary is advancing a project with a global satellite operator in South America, focusing on software licensing and product delivery [7] Group 5 - Hefei China announced a 1% reduction in shares by its controlling shareholder, who terminated the reduction plan early to express confidence in the company's future [8] - Weigao Blood Purification plans to acquire 100% equity of Weigao Purui for 8.511 billion yuan, which will expand its business into drug delivery systems [10]

2026年1月5日，A股市场整体上涨。 截至收盘，上证指数收报4023.42点，上涨1.38%，深证成指收报13828.63点，上涨2.24%，创业板指收报3294.55点，上涨2.85%，北证50指数上涨1.8%。A 股市场合计成交25674.1亿元，较上一交易日增加5015.79亿元。 | | | 今日资金净流出前五大行业 | | | --- | --- | --- | --- | | 行业 | 涨跌幅 | 净流入资金 (亿元) | 资金流出较多个股 | | 国防军工 | 2. 01% | -50. 22 | 航天电子 | | 汽车 | 0. 37% | -37.00 | 山子高科 | | 交通运输 | -0. 15% | -26.94 | 中远海控 | | 银行 | -0. 13% | -23.14 | 工商银行 | | 石油石化 | 0. 84% | -18. 38 | 中国海海 | 1.A股市场全天主力资金净流出62.98亿元 今日A股市场主力资金开盘净流出54.18亿元，尾盘净流入17.34亿元，A股市场全天主力资金净流出62.98亿元。 | | | 沪深两市近五日主力资金流向情况(亿元) | | ...

Group 1 - The integration of AI in healthcare is accelerating drug development, enhancing clinical precision, and driving innovation in the medical industry, providing stronger technological support for public health [1][2] - The AI platform "AI Kongming" has been launched, offering free access to databases related to global health challenges, significantly improving candidate molecule hit rates and optimization efficiency by several times compared to traditional processes [1][2] - AI technologies are increasingly applied across various medical fields, including drug development, medical imaging, disease diagnosis, and health monitoring, showcasing their versatility and potential impact [2][3] Group 2 - Major pharmaceutical companies like Shijiazhuang Pharmaceutical Group and Hengrui Medicine are establishing AI research departments to accelerate drug target discovery and clinical trial processes [3][4] - The establishment of innovation platforms, such as the one in Suzhou Industrial Park, aims to facilitate the transformation of medical and engineering innovations, breaking down barriers between data, disciplines, and institutions [4][5] - National policies are being introduced to promote the integration of new information technologies with the pharmaceutical industry, enhancing the application of AI in clinical settings [4][5]